Compare Stocks

5 / 10
Try these comparisons:

Stock Comparison

AFJK vs CANG vs BTBT vs CLOV vs ACMR

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
AFJK
Aimei Health Technology Co., Ltd

Shell Companies

Financial ServicesNASDAQ • US
Market Cap$261M
5Y Perf.+319.2%
CANG
Cango Inc.

Auto - Dealerships

Consumer CyclicalNYSE • CN
Market Cap$250M
5Y Perf.-9.8%
BTBT
Bit Digital, Inc.

Financial - Capital Markets

Financial ServicesNASDAQ • US
Market Cap$589M
5Y Perf.-30.7%
CLOV
Clover Health Investments, Corp.

Medical - Healthcare Plans

HealthcareNASDAQ • US
Market Cap$1.44B
5Y Perf.+194.3%
ACMR
ACM Research, Inc.

Semiconductors

TechnologyNASDAQ • US
Market Cap$3.92B
5Y Perf.+243.8%

AFJK vs CANG vs BTBT vs CLOV vs ACMR — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
AFJK logoAFJK
CANG logoCANG
BTBT logoBTBT
CLOV logoCLOV
ACMR logoACMR
IndustryShell CompaniesAuto - DealershipsFinancial - Capital MarketsMedical - Healthcare PlansSemiconductors
Market Cap$261M$250M$589M$1.44B$3.92B
Revenue (TTM)$0.00$3.46B$164M$2.21B$901M
Net Income (TTM)$1M$-178M$137M$-57M$94M
Gross Margin13.6%61.9%42.5%44.4%
Operating Margin7.3%16.8%-2.6%12.1%
Forward P/E251.0x5.7x9.2x65.9x29.7x
Total Debt$2M$170M$14M$0.00$303M
Cash & Equiv.$3K$1.29B$95M$78M$766M

AFJK vs CANG vs BTBT vs CLOV vs ACMRLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

AFJK
CANG
BTBT
CLOV
ACMR
StockJan 24May 26Return
Aimei Health Techno… (AFJK)100419.2+319.2%
Cango Inc. (CANG)10090.2-9.8%
Bit Digital, Inc. (BTBT)10069.3-30.7%
Clover Health Inves… (CLOV)100294.3+194.3%
ACM Research, Inc. (ACMR)100343.8+243.8%

Price return only. Dividends and distributions are not included.

Quick Verdict: AFJK vs CANG vs BTBT vs CLOV vs ACMR

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: BTBT leads in 4 of 7 categories (5-stock set), making it the strongest pick for growth and revenue expansion and profitability and margin quality. Aimei Health Technology Co., Ltd is the stronger pick specifically for capital preservation and lower volatility and recent price momentum and sentiment. CANG also leads in specific categories worth noting. This set spans 3 sectors — these stocks serve different portfolio roles, not just different price points.
AFJK
Aimei Health Technology Co., Ltd
The Banking Pick

AFJK is the #2 pick in this set and the best alternative if stability and momentum is your priority.

  • Beta 0.23 vs BTBT's 3.37
  • +288.0% vs CANG's -73.7%
Best for: stability and momentum
CANG
Cango Inc.
The Defensive Pick

CANG ranks third and is worth considering specifically for sleep-well-at-night.

  • Lower volatility, beta 2.25, Low D/E 4.1%, current ratio 1.88x
  • Lower P/E (5.7x vs 29.7x)
Best for: sleep-well-at-night
BTBT
Bit Digital, Inc.
The Banking Pick

BTBT carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.

  • Dividend streak 0 yrs, beta 3.37, yield 0.3%
  • Rev growth 264.6%, EPS growth 225.0%
  • Beta 3.37, yield 0.3%, current ratio 5.39x
  • 264.6% NII/revenue growth vs AFJK's -57.2%
Best for: income & stability and growth exposure
CLOV
Clover Health Investments, Corp.
The Insurance Play

CLOV lags the leaders in this set but could rank higher in a more targeted comparison.

Best for: healthcare exposure
ACMR
ACM Research, Inc.
The Long-Run Compounder

ACMR is the clearest fit if your priority is long-term compounding.

  • 30.7% 10Y total return vs AFJK's 320.4%
Best for: long-term compounding
See the full category breakdown
CategoryWinnerWhy
GrowthBTBT logoBTBT264.6% NII/revenue growth vs AFJK's -57.2%
ValueCANG logoCANGLower P/E (5.7x vs 29.7x)
Quality / MarginsBTBT logoBTBT17.3% margin vs CANG's -5.2%
Stability / SafetyAFJK logoAFJKBeta 0.23 vs BTBT's 3.37
DividendsBTBT logoBTBT0.3% yield, vs ACMR's 0.2%, (3 stocks pay no dividend)
Momentum (1Y)AFJK logoAFJK+288.0% vs CANG's -73.7%
Efficiency (ROA)BTBT logoBTBT19.0% ROA vs CLOV's -9.6%, ROIC 6.5% vs -34.0%

AFJK vs CANG vs BTBT vs CLOV vs ACMR — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

AFJKAimei Health Technology Co., Ltd

Segment breakdown not available.

CANGCango Inc.
FY 2024
After-market Service Facilitation Service Income
62.9%$41M
Loan Facilitation Income And Other Related Income
24.1%$16M
Automobile trading income
9.6%$6M
Service, Other
3.4%$2M
BTBTBit Digital, Inc.
FY 2024
Other Member
100.0%$550,260
CLOVClover Health Investments, Corp.
FY 2025
Insurance Segment
100.0%$50M
ACMRACM Research, Inc.
FY 2025
Total Single Wafer and Semi-Critical Cleaning Equipment
69.5%$626M
ECP Front End And Packaging Furnace And Other Technologies
22.1%$200M
Advanced Packaging (exclude ECP), Services & Spares
8.4%$76M

AFJK vs CANG vs BTBT vs CLOV vs ACMR — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLBTBTLAGGINGCLOV

Income & Cash Flow (Last 12 Months)

BTBT leads this category, winning 3 of 6 comparable metrics.

CANG and AFJK operate at a comparable scale, with $3.5B and $0 in trailing revenue. BTBT is the more profitable business, keeping 17.3% of every revenue dollar as net income compared to CANG's -5.2%. On growth, CANG holds the edge at +58.3% YoY revenue growth, suggesting stronger near-term business momentum.

MetricAFJK logoAFJKAimei Health Tech…CANG logoCANGCango Inc.BTBT logoBTBTBit Digital, Inc.CLOV logoCLOVClover Health Inv…ACMR logoACMRACM Research, Inc.
RevenueTrailing 12 months$0$3.5B$164M$2.2B$901M
EBITDAEarnings before interest/tax-$835,759$333M$166M-$55M$126M
Net IncomeAfter-tax profit$1M-$178M$137M-$57M$94M
Free Cash FlowCash after capex-$565,100$0-$448M$55M-$69M
Gross MarginGross profit ÷ Revenue+13.6%+61.9%+42.5%+44.4%
Operating MarginEBIT ÷ Revenue+7.3%+16.8%-2.6%+12.1%
Net MarginNet income ÷ Revenue-5.2%+17.3%-2.6%+10.4%
FCF MarginFCF ÷ Revenue-154.0%-65.3%+2.5%-7.6%
Rev. Growth (YoY)Latest quarter vs prior year+58.3%+62.0%+9.4%
EPS Growth (YoY)Latest quarter vs prior year-59.1%+3.6%+2.8%-76.1%
BTBT leads this category, winning 3 of 6 comparable metrics.

Valuation Metrics

Evenly matched — CANG and CLOV each lead in 2 of 5 comparable metrics.

At 5.7x trailing earnings, CANG trades at a 98% valuation discount to AFJK's 251.0x P/E. On an enterprise value basis, CANG's 3.1x EV/EBITDA is more attractive than ACMR's 27.5x.

MetricAFJK logoAFJKAimei Health Tech…CANG logoCANGCango Inc.BTBT logoBTBTBit Digital, Inc.CLOV logoCLOVClover Health Inv…ACMR logoACMRACM Research, Inc.
Market CapShares × price$261M$250M$589M$1.4B$3.9B
Enterprise ValueMkt cap + debt − cash$263M$85M$508M$1.4B$3.5B
Trailing P/EPrice ÷ TTM EPS251.03x5.66x9.15x-16.59x43.21x
Forward P/EPrice ÷ next-FY EPS est.65.89x29.68x
PEG RatioP/E ÷ EPS growth rate1.22x
EV / EBITDAEnterprise value multiple3.13x8.49x27.49x
Price / SalesMarket cap ÷ Revenue2.12x3.60x0.75x4.35x
Price / BookPrice ÷ Book value/share21.48x0.42x0.56x4.72x2.06x
Price / FCFMarket cap ÷ FCF
Evenly matched — CANG and CLOV each lead in 2 of 5 comparable metrics.

Profitability & Efficiency

BTBT leads this category, winning 5 of 9 comparable metrics.

BTBT delivers a 21.4% return on equity — every $100 of shareholder capital generates $21 in annual profit, vs $-17 for CLOV. BTBT carries lower financial leverage with a 0.03x debt-to-equity ratio, signaling a more conservative balance sheet compared to AFJK's 0.25x. On the Piotroski fundamental quality scale (0–9), BTBT scores 6/9 vs ACMR's 2/9, reflecting solid financial health.

MetricAFJK logoAFJKAimei Health Tech…CANG logoCANGCango Inc.BTBT logoBTBTBit Digital, Inc.CLOV logoCLOVClover Health Inv…ACMR logoACMRACM Research, Inc.
ROE (TTM)Return on equity+3.2%-4.1%+21.4%-17.1%+6.1%
ROA (TTM)Return on assets+2.9%-2.3%+19.0%-9.6%+3.9%
ROICReturn on invested capital-1.5%+4.6%+6.5%-34.0%+7.0%
ROCEReturn on capital employed-2.0%+4.5%+8.5%-24.5%+6.6%
Piotroski ScoreFundamental quality 0–924622
Debt / EquityFinancial leverage0.25x0.04x0.03x0.16x
Net DebtTotal debt minus cash$2M-$1.1B-$81M-$78M-$463M
Cash & Equiv.Liquid assets$2,929$1.3B$95M$78M$766M
Total DebtShort + long-term debt$2M$170M$14M$0$303M
Interest CoverageEBIT ÷ Interest expense-1.87x20.44x
BTBT leads this category, winning 5 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

ACMR leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in AFJK five years ago would be worth $42,044 today (with dividends reinvested), compared to $1,543 for BTBT. Over the past 12 months, AFJK leads with a +288.0% total return vs CANG's -73.7%. The 3-year compound annual growth rate (CAGR) favors ACMR at 80.5% vs BTBT's -7.1% — a key indicator of consistent wealth creation.

MetricAFJK logoAFJKAimei Health Tech…CANG logoCANGCango Inc.BTBT logoBTBTBit Digital, Inc.CLOV logoCLOVClover Health Inv…ACMR logoACMRACM Research, Inc.
YTD ReturnYear-to-date-43.7%-62.0%-10.3%+17.0%+31.9%
1-Year ReturnPast 12 months+288.0%-73.7%-9.0%-25.2%+195.6%
3-Year ReturnCumulative with dividends+320.4%+1.2%-19.7%+221.7%+487.9%
5-Year ReturnCumulative with dividends+320.4%-14.2%-84.6%-67.3%+133.4%
10-Year ReturnCumulative with dividends+320.4%-44.9%-60.4%-72.4%+3065.8%
CAGR (3Y)Annualised 3-year return+61.4%+0.4%-7.1%+47.6%+80.5%
ACMR leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

Evenly matched — AFJK and ACMR each lead in 1 of 2 comparable metrics.

AFJK is the less volatile stock with a 0.23 beta — it tends to amplify market swings less than BTBT's 3.37 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ACMR currently trades 82.6% from its 52-week high vs CANG's 18.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricAFJK logoAFJKAimei Health Tech…CANG logoCANGCango Inc.BTBT logoBTBTBit Digital, Inc.CLOV logoCLOVClover Health Inv…ACMR logoACMRACM Research, Inc.
Beta (5Y)Sensitivity to S&P 5000.23x2.25x3.37x1.22x3.24x
52-Week HighHighest price in past year$130.37$2.88$4.55$3.92$71.65
52-Week LowLowest price in past year$6.75$0.33$1.25$1.58$19.26
% of 52W HighCurrent price vs 52-week peak+32.7%+18.6%+40.2%+71.9%+82.6%
RSI (14)Momentum oscillator 0–10054.258.669.169.560.7
Avg Volume (50D)Average daily shares traded21K1.3M18.5M5.6M1.2M
Evenly matched — AFJK and ACMR each lead in 1 of 2 comparable metrics.

Analyst Outlook

Evenly matched — CANG and BTBT each lead in 1 of 2 comparable metrics.

Analyst consensus: CANG as "Buy", BTBT as "Buy", CLOV as "Hold", ACMR as "Buy". Consensus price targets imply 459.2% upside for CANG (target: $3) vs -32.4% for ACMR (target: $40). For income investors, BTBT offers the higher dividend yield at 0.31% vs ACMR's 0.19%.

MetricAFJK logoAFJKAimei Health Tech…CANG logoCANGCango Inc.BTBT logoBTBTBit Digital, Inc.CLOV logoCLOVClover Health Inv…ACMR logoACMRACM Research, Inc.
Analyst RatingConsensus buy/hold/sellBuyBuyHoldBuy
Price TargetConsensus 12-month target$3.00$5.00$3.33$40.00
# AnalystsCovering analysts22910
Dividend YieldAnnual dividend ÷ price+0.3%+0.2%
Dividend StreakConsecutive years of raises503
Dividend / ShareAnnual DPS$0.01$0.11
Buyback YieldShare repurchases ÷ mkt cap0.0%+5.3%0.0%+3.8%+0.2%
Evenly matched — CANG and BTBT each lead in 1 of 2 comparable metrics.
Key Takeaway

BTBT leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). ACMR leads in 1 (Total Returns). 3 tied.

Best OverallBit Digital, Inc. (BTBT)Leads 2 of 6 categories
Loading custom metrics...

AFJK vs CANG vs BTBT vs CLOV vs ACMR: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is AFJK or CANG or BTBT or CLOV or ACMR a better buy right now?

For growth investors, Bit Digital, Inc.

(BTBT) is the stronger pick with 264. 6% revenue growth year-over-year, versus -52. 7% for Cango Inc. (CANG). Cango Inc. (CANG) offers the better valuation at 5. 7x trailing P/E, making it the more compelling value choice. Analysts rate Cango Inc. (CANG) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — AFJK or CANG or BTBT or CLOV or ACMR?

On trailing P/E, Cango Inc.

(CANG) is the cheapest at 5. 7x versus Aimei Health Technology Co. , Ltd at 251. 0x. On forward P/E, ACM Research, Inc. is actually cheaper at 29. 7x — notably different from the trailing picture, reflecting expected earnings growth.

03

Which is the better long-term investment — AFJK or CANG or BTBT or CLOV or ACMR?

Over the past 5 years, Aimei Health Technology Co.

, Ltd (AFJK) delivered a total return of +320. 4%, compared to -84. 6% for Bit Digital, Inc. (BTBT). Over 10 years, the gap is even starker: ACMR returned +30. 7% versus CLOV's -72. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — AFJK or CANG or BTBT or CLOV or ACMR?

By beta (market sensitivity over 5 years), Aimei Health Technology Co.

, Ltd (AFJK) is the lower-risk stock at 0. 23β versus Bit Digital, Inc. 's 3. 37β — meaning BTBT is approximately 1343% more volatile than AFJK relative to the S&P 500. On balance sheet safety, Bit Digital, Inc. (BTBT) carries a lower debt/equity ratio of 3% versus 25% for Aimei Health Technology Co. , Ltd — giving it more financial flexibility in a downturn.

05

Which is growing faster — AFJK or CANG or BTBT or CLOV or ACMR?

By revenue growth (latest reported year), Bit Digital, Inc.

(BTBT) is pulling ahead at 264. 6% versus -52. 7% for Cango Inc. (CANG). On earnings-per-share growth, the picture is similar: Cango Inc. grew EPS 960. 0% year-over-year, compared to -93. 6% for Clover Health Investments, Corp.. Over a 3-year CAGR, ACMR leads at 32. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — AFJK or CANG or BTBT or CLOV or ACMR?

Cango Inc.

(CANG) is the more profitable company, earning 37. 3% net margin versus -4. 4% for Clover Health Investments, Corp. — meaning it keeps 37. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CANG leads at 22. 2% versus -4. 4% for CLOV. At the gross margin level — before operating expenses — BTBT leads at 61. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is AFJK or CANG or BTBT or CLOV or ACMR more undervalued right now?

On forward earnings alone, ACM Research, Inc.

(ACMR) trades at 29. 7x forward P/E versus 65. 9x for Clover Health Investments, Corp. — 36. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CANG: 459. 2% to $3. 00.

08

Which pays a better dividend — AFJK or CANG or BTBT or CLOV or ACMR?

In this comparison, BTBT (0.

3% yield), ACMR (0. 2% yield) pay a dividend. AFJK, CANG, CLOV do not pay a meaningful dividend and should not be held primarily for income.

09

Is AFJK or CANG or BTBT or CLOV or ACMR better for a retirement portfolio?

For long-horizon retirement investors, Aimei Health Technology Co.

, Ltd (AFJK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 23), +320. 4% 10Y return). Bit Digital, Inc. (BTBT) carries a higher beta of 3. 37 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (AFJK: +320. 4%, BTBT: -60. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between AFJK and CANG and BTBT and CLOV and ACMR?

These companies operate in different sectors (AFJK (Financial Services) and CANG (Consumer Cyclical) and BTBT (Financial Services) and CLOV (Healthcare) and ACMR (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: AFJK is a small-cap quality compounder stock; CANG is a small-cap deep-value stock; BTBT is a small-cap high-growth stock; CLOV is a small-cap high-growth stock; ACMR is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

AFJK

Quality Business

  • Sector: Financial Services
  • Market Cap > $100B
Run This Screen
Stocks Like

CANG

High-Growth Disruptor

  • Sector: Consumer Cyclical
  • Market Cap > $100B
  • Revenue Growth > 2916%
Run This Screen
Stocks Like

BTBT

High-Growth Compounder

  • Sector: Financial Services
  • Market Cap > $100B
  • Revenue Growth > 132%
  • Net Margin > 10%
Run This Screen
Stocks Like

CLOV

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 31%
  • Gross Margin > 25%
Run This Screen
Stocks Like

ACMR

Steady Growth Compounder

  • Sector: Technology
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 6%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform AFJK and CANG and BTBT and CLOV and ACMR on the metrics below

P/E Ratio<
x
(AFJK: 251.0x · CANG: 5.7x)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.